
Formation Bio is a tech and AI driven pharma company differentiated by radically more efficient drug development.
Advancements in AI and drug discovery are creating more candidate drugs than the industry can progress because of the high cost and time of clinical trials. Recognizing that this development bottleneck may ultimately limit the number of new medicines that can reach patients, Formation Bio, founded in 2016 as TrialSpark Inc., has built technology platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies, research organizations, and biotechs to develop programs past clinical proof of concept and beyond, ultimately helping to bring new medicines to patients. The company is backed by investors across pharma and tech, including a16z, Sequoia, Sanofi, Thrive Capital, Sam Altman, John Doerr, Spark Capital, SV Angel Growth, and others.
You can read more at the following links:
At Formation Bio, our values are the driving force behind our mission to revolutionize the pharma industry. Every team and individual at the company shares these same values, and every team and individual plays a key part in our mission to bring new treatments to patients faster and more efficiently.
We're looking for a Senior Data Engineer to join the Scientific Data Intelligence (SDI) team at Formation Bio to help transform Real World Data (RWD)—spanning electronic health records, claims, and other longitudinal patient data sources—into structured, analytics-ready assets. In this role, you'll be partnering closely with our Data Science team not only to model and transform data, but also to actively analyze it: answering research questions, generating evidence, and supporting scientific decision-making across our drug portfolio.
This position sits at the intersection of healthcare data engineering, real-world evidence analysis, and generative AI. While a strong foundation in building reliable, scalable pipelines is essential, you'll be equally expected to roll up your sleeves and work directly with the data—constructing cohorts, running analyses, and translating findings into actionable insights for scientific and business stakeholders.
The ideal candidate is a hybrid of data engineer and applied scientist: someone who can build the infrastructure and then use it, with familiarity in RWD study design, GenAI fluency (e.g., LLM-based entity extraction, summarization, classification), and strong technical expertise with modern data tooling. You'll play a key role in shaping how real-world patient data becomes discoverable, structured, and impactful across the organization.
Formation Bio is prioritizing hiring in key hubs, primarily the New York City and Boston metro areas. These positions will follow a hybrid work model with 1-3 days required at the office. Applicants from the Research Triangle (NC) and San Francisco Bay Area may also be considered. Please only apply if you reside in these locations or are willing to relocate.
Compensation Range: $204,500 - $267,000
Salary ranges are informed by a number of factors including geographic location. The range provided includes base salary only. In addition to base salary, we offer equity, comprehensive benefits, generous perks, hybrid flexibility, and more. If this range doesn't match your expectations, please still apply because we may have something else for you.
You will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. The company has built proprietary technology platforms to optimize critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. Formation Bio acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop assets faster, unlocking greater value per program and ultimately accelerate access to new treatments for patients.
2025 CNBC Disruptor 50
2025 Fierce 15 Award
2024 Endpoints 11 Award